Belvedere Trading
ALT icon

Belvedere Trading’s Altimmune ALT Stock Holding History

Belvedere Trading’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,700
Closed -$19.1K – 672
2023
Q4 		$19.1K Buy
+1,700
New +$7.1K ﹤0.01% 655
2023
Q1 		– Sell
-25,700
Closed -$423K – 900
2022
Q4 		$423K Buy
+25,700
New +$289K ﹤0.01% 160

Other funds holding ALT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Belvedere Trading's ALT Position: Q1 2024 in Review

Belvedere Trading sold out of Altimmune (ALT) in Q1 2024, closing a stake of 16,755 shares — an estimated $188K sold.

Belvedere Trading first reported a position in ALT in Q3 2021 and held it in 3 quarters. The position peaked at $288K in Q4 2022. 172 funds tracked by Wall St. Rank hold ALT as of Q1 2024.

  • Belvedere Trading reported no remaining Altimmune position as of Q1 2024 after selling out during the quarter.
  • Belvedere Trading sold 16,755 Altimmune shares in Q1 2024, an estimated $188K.
  • Belvedere Trading first reported a position in Altimmune in Q3 2021 and held it in 3 quarters.
  • Belvedere Trading's Altimmune position peaked at $288K in Q4 2022.
  • 172 funds tracked by Wall St. Rank held Altimmune as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.